Lilly to supply 388,000 doses of etesevimab to U.S. government for treatment of COVID-19

lilly to supply 388000 doses of etesevimab to u s government for treatment of covid 19

Sumary of Lilly to supply 388,000 doses of etesevimab to U.S. government for treatment of COVID-19:

  • For more information about the use of bamlanivimab with etesevimab to treat COVID-19, click here or contact Lilly’s 24-hour support line at 1-855-LillyC19 (1-855-545-5921).
  • Treatment with bamlanivimab and etesevimab together has not been studied in patients hospitalized due to COVID-19. Monoclonal antibodies, such as bamlanivimab and etesevimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation.
  • Serious and unexpected adverse events may occur that have not been previously reported with bamlanivimab and etesevimab together.
  • Warnings and PrecautionsHypersensitivity Including Anaphylaxis and Infusion-Related ReactionsSerious hypersensitivity reactions, including anaphylaxis, have been observed with administration of bamlanivimab and etesevimab.
  • Infusion-related reactions, occurring during or up to 24 hours after infusion, have been observed with administration of bamlanivimab and etesevimab together.
  • Signs and symptoms of infusion-related reactions may include:fever, difficulty breathing, reduced oxygen saturation, chills, fatigue, arrhythmia (e.
  • atrial fibrillation, sinus tachycardia, bradycardia), chest pain or discomfort, weakness, altered mental status, nausea, headache, bronchospasm, hypotension, hypertension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, vasovagal reactions (e.
  • Hypersensitivity reactions occurring more than 24 hours after the infusion have also been reported with the use of bamlanivimab and etesevimab under Emergency Use Authorization.

Want to know more click here go to source.

From -

Close
Generic selectors
Exact matches only
Search in title
Search in content

Site Language


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close